Literature DB >> 23036769

Stevens-Johnson syndrome induced by levetiracetam.

Li-Ping Zou1, Chang-Hong Ding, Zhen-Jiang Song, Xiao-Feng Li.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23036769     DOI: 10.1016/j.seizure.2012.09.005

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


× No keyword cloud information.
  6 in total

1.  Carbamazepine-induced Life-threatening Stevens-Johnson Syndrome and Agranulocytosis: The Maiden Case.

Authors:  A Avinash; V Mohanbabu Amberkar; Sushil Kiran Kunder; Sharath Madhyastha; K Meenakumari
Journal:  J Clin Diagn Res       Date:  2016-12-01

Review 2.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

3.  Spectrum of Cutaneous Adverse Reactions to Levetiracetam and Human Leukocyte Antigen Typing in North-Indian Patients.

Authors:  Bhargavi Ramanujam; Kavish Ihtisham; Gurvinder Kaur; Shivani Srivastava; Narinder Kumar Mehra; Neena Khanna; Mahip Singh; Manjari Tripathi
Journal:  J Epilepsy Res       Date:  2016-12-31

Review 4.  Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities.

Authors:  Adegbenro Omotuyi John Fakoya; Princess Omenyi; Precious Anthony; Favour Anthony; Precious Etti; David Adeiza Otohinoyi; Esther Olunu
Journal:  Open Access Maced J Med Sci       Date:  2018-03-28

5.  B cell aplasia and hypogammaglobulinemia associated with levetiracetam.

Authors:  Hulya Ozdemir; Sua Sumer; Hakan Karabagli; Gokhan Akdemir; A Zafer Caliskaner; Hasibe Artac
Journal:  Ann Saudi Med       Date:  2018-01-09       Impact factor: 1.526

6.  Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles.

Authors:  Zhan-Miao Yi; Cheng Wen; Ting Cai; Lu Xu; Xu-Li Zhong; Si-Yan Zhan; Suo-Di Zhai
Journal:  Neuropsychiatr Dis Treat       Date:  2018-12-17       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.